Artificial Intelligence
Pharma's AI Power Grab: Novo-OpenAI and Novartis-Anthropic Ties
Novo Nordisk's blockbuster OpenAI deal and Novartis CEO's seat on Anthropic's board signal Big Pharma's aggressive AI push. But will it deliver breakthrough drugs or just fatten tech giants' wallets?
Lavamgam AIApr 15, 20263 min read read
The Debate
Big Pharma has long chased miracles in labs, but now it's betting billions on AI wizards from Silicon Valley. Novo Nordisk's fresh partnership with OpenAI and Novartis CEO Vas Narasimhan landing a board seat at Anthropic raise a sharp question: Are these moves the spark for revolutionizing drug discovery, slashing years off development timelines, or just savvy PR to appease investors amid fierce obesity drug wars?
The Case For
These aren't token gestures—they're full-throttle...
AI pharma
Novo Nordisk
OpenAI
Novartis
Anthropic
drug discovery
Vas Narasimhan
obesity drugs
Share